S&P 500   5,135.31 (-0.03%)
DOW   38,993.71 (-0.24%)
QQQ   444.89 (-0.16%)
AAPL   174.32 (-2.97%)
MSFT   415.70 (+0.05%)
META   501.09 (-0.24%)
GOOGL   132.60 (-3.31%)
AMZN   178.05 (-0.10%)
TSLA   187.14 (-7.65%)
NVDA   866.80 (+5.35%)
NIO   5.28 (-8.65%)
AMD   207.40 (+2.35%)
BABA   71.80 (-3.78%)
T   16.80 (-1.06%)
F   12.84 (+3.13%)
MU   96.78 (+1.71%)
CGC   3.00 (-6.54%)
GE   160.63 (+1.25%)
DIS   113.67 (+1.54%)
AMC   4.31 (-1.15%)
PFE   25.77 (-3.08%)
PYPL   59.63 (-1.50%)
XOM   104.42 (-1.34%)
S&P 500   5,135.31 (-0.03%)
DOW   38,993.71 (-0.24%)
QQQ   444.89 (-0.16%)
AAPL   174.32 (-2.97%)
MSFT   415.70 (+0.05%)
META   501.09 (-0.24%)
GOOGL   132.60 (-3.31%)
AMZN   178.05 (-0.10%)
TSLA   187.14 (-7.65%)
NVDA   866.80 (+5.35%)
NIO   5.28 (-8.65%)
AMD   207.40 (+2.35%)
BABA   71.80 (-3.78%)
T   16.80 (-1.06%)
F   12.84 (+3.13%)
MU   96.78 (+1.71%)
CGC   3.00 (-6.54%)
GE   160.63 (+1.25%)
DIS   113.67 (+1.54%)
AMC   4.31 (-1.15%)
PFE   25.77 (-3.08%)
PYPL   59.63 (-1.50%)
XOM   104.42 (-1.34%)
S&P 500   5,135.31 (-0.03%)
DOW   38,993.71 (-0.24%)
QQQ   444.89 (-0.16%)
AAPL   174.32 (-2.97%)
MSFT   415.70 (+0.05%)
META   501.09 (-0.24%)
GOOGL   132.60 (-3.31%)
AMZN   178.05 (-0.10%)
TSLA   187.14 (-7.65%)
NVDA   866.80 (+5.35%)
NIO   5.28 (-8.65%)
AMD   207.40 (+2.35%)
BABA   71.80 (-3.78%)
T   16.80 (-1.06%)
F   12.84 (+3.13%)
MU   96.78 (+1.71%)
CGC   3.00 (-6.54%)
GE   160.63 (+1.25%)
DIS   113.67 (+1.54%)
AMC   4.31 (-1.15%)
PFE   25.77 (-3.08%)
PYPL   59.63 (-1.50%)
XOM   104.42 (-1.34%)
S&P 500   5,135.31 (-0.03%)
DOW   38,993.71 (-0.24%)
QQQ   444.89 (-0.16%)
AAPL   174.32 (-2.97%)
MSFT   415.70 (+0.05%)
META   501.09 (-0.24%)
GOOGL   132.60 (-3.31%)
AMZN   178.05 (-0.10%)
TSLA   187.14 (-7.65%)
NVDA   866.80 (+5.35%)
NIO   5.28 (-8.65%)
AMD   207.40 (+2.35%)
BABA   71.80 (-3.78%)
T   16.80 (-1.06%)
F   12.84 (+3.13%)
MU   96.78 (+1.71%)
CGC   3.00 (-6.54%)
GE   160.63 (+1.25%)
DIS   113.67 (+1.54%)
AMC   4.31 (-1.15%)
PFE   25.77 (-3.08%)
PYPL   59.63 (-1.50%)
XOM   104.42 (-1.34%)
NASDAQ:MACK

Merrimack Pharmaceuticals (MACK) Stock Price, News & Analysis

$14.72
-0.02 (-0.14%)
(As of 01:31 PM ET)
Today's Range
$14.70
$14.77
50-Day Range
$13.06
$15.00
52-Week Range
$11.25
$15.89
Volume
43,608 shs
Average Volume
107,930 shs
Market Capitalization
$210.79 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A

Merrimack Pharmaceuticals MarketRank™ Stock Analysis

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Bearish
5.75% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.89mentions of Merrimack Pharmaceuticals in the last 14 days
Based on 2 Articles This Week
Insider Trading
Acquiring Shares
$1.95 M Bought Last Quarter
Proj. Earnings Growth
N/A

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

0.69 out of 5 stars


MACK stock logo

About Merrimack Pharmaceuticals Stock (NASDAQ:MACK)

Merrimack Pharmaceuticals, Inc. operates as a biopharmaceutical company. The company was incorporated in 1993 and is headquartered in Cambridge, Massachusetts.

MACK Stock Price History

MACK Stock News Headlines

Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
MACK Mar 2024 14.000 put
MACK Mar 2024 4.000 put
MACK Feb 2024 16.000 put
Ipsen drug approved by FDA for early pancreatic cancer
Critical asset just had biggest fall on record
What many consider America's critical financial asset suffers biggest fall on record. Expert says: "it's very bad for millions, protect yourself now."
Merrimack Pharmaceuticals Inc MACK
Merrimack Reports Third Quarter 2023 Financial Results
Merrimack Valley High School
See More Headlines
Receive MACK Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Merrimack Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
5/10/2019
Today
3/04/2024
Next Earnings (Estimated)
3/14/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:MACK
CUSIP
59032810
Employees
426
Year Founded
2000

Profitability

Net Income
$-1,540,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$1.44 per share

Miscellaneous

Free Float
10,187,000
Market Cap
$211.08 million
Optionable
Optionable
Beta
1.44

Social Links

Growth stocks offer a lot of bang for your buck, and we've got the next upcoming superstars to strongly consider for your portfolio.

Get This Free Report














MACK Stock Analysis - Frequently Asked Questions

How have MACK shares performed in 2024?

Merrimack Pharmaceuticals' stock was trading at $13.41 at the start of the year. Since then, MACK stock has increased by 9.8% and is now trading at $14.72.
View the best growth stocks for 2024 here
.

When is Merrimack Pharmaceuticals' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 14th 2024.
View our MACK earnings forecast
.

How were Merrimack Pharmaceuticals' earnings last quarter?

Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) issued its earnings results on Friday, May, 10th. The biopharmaceutical company reported ($0.78) EPS for the quarter, topping the consensus estimate of ($0.92) by $0.14.

When did Merrimack Pharmaceuticals' stock split?

Shares of Merrimack Pharmaceuticals reverse split on the morning of Wednesday, September 6th 2017. The 1-10 reverse split was announced on Thursday, August 31st 2017. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, September 5th 2017. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

What other stocks do shareholders of Merrimack Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Merrimack Pharmaceuticals investors own include Agenus (AGEN), Inovio Pharmaceuticals (INO), Rite Aid (RAD), Anavex Life Sciences (AVXL), Gilead Sciences (GILD), Novavax (NVAX), Exelixis (EXEL), Amicus Therapeutics (FOLD), Bausch Health Companies (BHC) and Verastem (VSTM).

Who are Merrimack Pharmaceuticals' major shareholders?

Merrimack Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (4.25%), ADAR1 Capital Management LLC (3.84%), Dimensional Fund Advisors LP (3.04%), Northern Trust Corp (0.82%), Barclays PLC (0.10%) and UBS Group AG (0.09%). Insiders that own company stock include Ana Radeljevic, Eric Andersen, Gary L Crocker, Noah G Levy and Ulrik B Nielsen.
View institutional ownership trends
.

How do I buy shares of Merrimack Pharmaceuticals?

Shares of MACK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:MACK) was last updated on 3/4/2024 by MarketBeat.com Staff